Alcoa Schedules First Quarter 2021 Earnings Release and Conference Call

Alcoa Schedules First Quarter 2021 Earnings Release and Conference Call

PITTSBURGH–(BUSINESS WIRE)–
Alcoa Corporation plans to announce its first quarter 2021 financial results on Thursday, April 15, 2021, after the close of trading on the New York Stock Exchange.

The press release with financial results, and a related presentation, will be available on the “Investors” section of Alcoa’s website, www.alcoa.com. A link to the press release will also be on Alcoa’s twitter handle @Alcoa at www.twitter.com/Alcoa.

A conference call to discuss the financial results will begin at 5:00 p.m. EDT, and will be webcast live via Alcoa’s website.

Conference Call Information

Time:

Thursday, April 15, 2021: 5:00 p.m.–6:00 p.m. EDT

 

Hosts:

Roy Harvey, President and Chief Executive Officer

William Oplinger, Executive Vice President and Chief Financial Officer

 

Call:

+1 (877) 883-0383 (Domestic)

+1 (412) 902-6506 (International)

Conference ID: 0530616

To avoid a delay in start time, please dial in beginning at 4:45 p.m.

 

Webcast:
Go to “Investors” section of the Alcoa website to listen only and view slides.

 

Replay Information
A telephone replay of the call will be available at approximately 8:00 p.m. EDT on April 15 until April 22, 2021. The webcast will be archived and available on the “Investors” section of www.alcoa.com.

 

Replay:

+1 (877) 344-7529 (Domestic)

+1 (412) 317-0088 (International)

Replay Access Code: 10152987 or on the Events section of our website.

To access the replay using an international dial-in number, please select this link:

https://services.choruscall.com/ccforms/replay.html

About Alcoa Corporation

Alcoa (NYSE: AA) is a global industry leader in bauxite, alumina, and aluminum products, and is built on a foundation of strong values and operating excellence dating back 135 years to the world-changing discovery that made aluminum an affordable and vital part of modern life. Since developing the aluminum industry, and throughout our history, our talented Alcoans have followed on with breakthrough innovations and best practices that have led to efficiency, safety, sustainability, and stronger communities wherever we operate.

Dissemination of Company Information

Alcoa intends to make future announcements regarding company developments and financial performance through its website, www.alcoa.com, as well as through press releases, filings with the Securities and Exchange Commission, conference calls and webcasts.

Investor Contact:

James Dwyer

412-992-5450

[email protected]

Media Contact:

Jim Beck

412-315-2909

[email protected]

KEYWORDS: United States North America Pennsylvania New York

INDUSTRY KEYWORDS: Engineering Mining/Minerals Manufacturing Natural Resources Other Manufacturing Steel

MEDIA:

Logo
Logo

Foley Trasimene Acquisition Corp. II Announces Stockholder Approval of Proposed Combination with Paysafe

Foley Trasimene Acquisition Corp. II Announces Stockholder Approval of Proposed Combination with Paysafe

LAS VEGAS–(BUSINESS WIRE)–
Foley Trasimene Acquisition Corp. II (NYSE: BFT, BFT WS) (“Foley Trasimene”), a special purpose acquisition company, announced that at the special meeting of Foley Trasimene stockholders (the “Special Meeting”) held today, Foley Trasimene’s stockholders voted in favor of the proposed business combination (the “Business Combination”) with Paysafe Group Holdings Limited (“Paysafe”). The completion of the Business Combination is expected to occur on Tuesday, March 30, 2021, subject to the satisfaction or waiver of customary closing conditions. Following the completion of the Business Combination, the newly combined company will operate as Paysafe and trade on the New York Stock Exchange (NYSE) under the symbol “PSFE” and is expected to start trading on Wednesday, March 31.

Additional Information on the Business Combination and Where to Find It

In connection with the proposed Business Combination, a registration statement on Form F-4 (the “Form F-4”) was filed (SEC File No. 333-251552) by Paysafe Limited, an exempted limited company incorporated under the laws of Bermuda (“Paysafe Limited”) with the Securities and Exchange Commission (the “SEC”), and declared effective on February 26, 2021, that includes a proxy statement that has been distributed to holders of Foley Trasimene’s common stock in connection with Foley Trasimene’s solicitation for proxies for the vote by Foley Trasimene’s stockholders in connection with the proposed Business Combination and other matters as described in the Form F-4, as well as a prospectus of Paysafe Limited relating to the offer of the securities to be issued in connection with the completion of the Business Combination. Foley Trasimene, Paysafe and Paysafe Limited urge investors, stockholders and other interested persons to read the Form F-4, including the proxy statement/prospectus included therein, as well as other documents filed with the SEC in connection with the proposed Business Combination, as these materials contain important information about Paysafe, Foley Trasimene, and the proposed Business Combination. Such persons can also read Foley Trasimene’s final prospectus dated August 20, 2020 (SEC File No. 333-240285), for a description of the security holdings of Foley Trasimene’s officers and directors and their respective interests as security holders in the consummation of the proposed Business Combination.

The definitive proxy statement/prospectus has been mailed to Foley Trasimene’s stockholders as of the record date established for voting on the proposed Business Combination. Stockholders are also able to obtain copies of such documents, without charge, at the SEC’s website at www.sec.gov, or by directing a request to: Foley Trasimene Acquisition Corp. II, 1701 Village Center Circle, Las Vegas, NV 89134, or (702) 323-7330.

About Foley Trasimene Acquisition Corp. II

Foley Trasimene Acquisition Corp. II is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. For more information, please visit www.foleytrasimene2.com.

About Paysafe

Paysafe Group (Paysafe) is a leading specialized payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through industry-leading capabilities in payment processing, digital wallet, and online cash solutions. With over 20 years of online payment experience, an annualized transactional volume of US $92 billion in 2020, and approximately 3,400 employees located in 12+ global locations, Paysafe connects businesses and consumers across 70 payment types in over 40 currencies around the world. Delivered through an integrated platform, Paysafe solutions are geared toward mobile-initiated transactions, real-time analytics and the convergence between brick-and-mortar and online payments. Further information is available at www.paysafe.com.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Foley Trasimene’s and Paysafe’s actual results may differ from their expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Foley Trasimene’s and Paysafe’s expectations with respect to future performance and anticipated financial impacts of the proposed Business Combination, the satisfaction or waiver of the closing conditions to the proposed Business Combination, and the timing of the completion of the proposed Business Combination.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially, and potentially adversely, from those expressed or implied in the forward-looking statements. Most of these factors are outside Foley Trasimene’s and Paysafe’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change, or other circumstances that could give rise to the termination of the definitive merger agreement (the “Agreement”); (2) the outcome of any legal proceedings that may be instituted against Foley Trasimene, Paysafe Limited and/or Paysafe following the announcement of the Agreement and the transactions contemplated therein; (3) the inability to complete the proposed Business Combination, including due to failure to obtain certain regulatory approvals, or satisfy other conditions to closing in the Agreement; (4) the occurrence of any event, change, or other circumstance that could give rise to the termination of the Agreement or could otherwise cause the transaction to fail to close; (5) the impact of COVID-19 on Paysafe’s business and/or the ability of the parties to complete the proposed Business Combination; (6) the inability to obtain or maintain the listing of Paysafe Limited’s common shares on the New York Stock Exchange following the proposed Business Combination; (7) the risk that the proposed Business Combination disrupts current plans and operations as a result of the announcement and consummation of the proposed Business Combination; (8) the ability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, competition, the ability of Paysafe to grow and manage growth profitably, and retain its key employees; (9) costs related to the proposed Business Combination; (10) changes in applicable laws or regulations; and (11) the possibility that Paysafe, Foley Trasimene or Paysafe Limited may be adversely affected by other economic, business, and/or competitive factors. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in Foley Trasimene’ s most recent filings with the SEC and in the Form F-4 (as defined herein), including the definitive proxy statement/prospectus filed in connection with the proposed Business Combination. All subsequent written and oral forward-looking statements concerning Foley Trasimene, Paysafe or Paysafe Limited, the transactions described herein or other matters and attributable to Foley Trasimene, Paysafe, Paysafe Limited or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Each of Foley Trasimene, Paysafe and Paysafe Limited expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based, except as required by law.

No Offer or Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed Business Combination and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Foley Trasimene, Paysafe Limited or Paysafe, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom.

Shannon Devine, Senior Vice President, Solebury Trout, 203-428-3228, [email protected]

KEYWORDS: United States North America Nevada

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Elastic Announces Optimized Data Architecture, Enhanced Web Crawler, and Autoscaling in Elastic Enterprise Search

Elastic Announces Optimized Data Architecture, Enhanced Web Crawler, and Autoscaling in Elastic Enterprise Search

Driving Value for Users by Reducing Deployment Size, Increasing Rate of Indexing, and Delivering More Relevant Search Results 

  • Building on an updated data architecture to deliver greater storage efficiency, search performance, and more relevant results.
  • Adding performance and stability improvements to the Elastic App Search web crawler and support for web crawling standards.
  • Extending autoscaling to Elastic Enterprise Search to allow users to proactively set rules that monitor storage usage and gain peace of mind.

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Elastic (NYSE: ESTC) (“Elastic”), the company behind Elasticsearch and the Elastic Stack, recently announced an updated data architecture, enhanced web crawler, and autoscaling to support consistent search performance, scalability, and relevancy across the Elastic Enterprise Search solution in the 7.12 release.

Elastic Enterprise Search introduces a reimagined underlying data architecture optimized for performance, relevance, and capacity management. With this new data structure, deployments may benefit from up to 70 percent improvement in storage efficiency, up to 40 percent reduction in indexing latency, and significant improvements to results relevance across App Search and Workplace Search.

The Elastic App Search web crawler, recently introduced in beta, adds several performance and stability improvements, along with better support for web crawling standards such as robot.txt. With the App Search web crawler, users can leverage simple point-and-click tools to extract publicly accessible web content into their App Search engine without any coding required.

Elastic Enterprise Search also inherits index lifecycle management (ILM) policies from the Elastic Stack to automatically manage logs and analytics, and can easily roll additional ILM features into App Search and Workplace Search.

Autoscaling on Elastic Cloud allows Enterprise Search users to proactively set predefined rules that monitor storage usage, whether that storage comes from content, logs, or analytics. When a threshold is met, autoscaling automatically increases customers’ storage capacity based on predefined rules. With autoscaling, users can drive greater insights into their search platform with less overhead.

For more information read the Elastic blog about what’s new in Elastic Enterprise Search 7.12.

About Elastic:

Elastic is a search company built on a free and open heritage. Anyone can use Elastic products and solutions to get started quickly and frictionlessly. Elastic offers three solutions for enterprise search, observability, and security, built on one technology stack that can be deployed anywhere. From finding documents to monitoring infrastructure to hunting for threats, Elastic makes data usable in real time and at scale. Thousands of organizations worldwide, including Cisco, eBay, Goldman Sachs, Microsoft, The Mayo Clinic, NASA, The New York Times, Wikipedia, and Verizon, use Elastic to power mission-critical systems. Founded in 2012, Elastic is a distributed company with Elasticians around the globe and is publicly traded on the NYSE under the symbol ESTC. Learn more at elastic.co.

The release and timing of any features or functionality described in this document remain at Elastic’s sole discretion. Any features or functionality not currently available may not be delivered on time or at all.

Elastic and associated marks are trademarks or registered trademarks of Elastic N.V. and its subsidiaries. All other company and product names may be trademarks of their respective owners.

Elastic Public Relations

Ariel Roop

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Internet

MEDIA:

Logo
Logo

Sun Life announces virtual Annual Meetings of shareholders and voting policyholders and availability of 2020 Annual Report, 2021 Management Information Circular and 2021 Information for Voting Policyholders’ Booklet

PR Newswire

Sun Life also announces the nomination of new directors for election

TORONTO, March 25, 2021 /PRNewswire/ – Sun Life Financial Inc. (TSX: SLF) (NYSE: SLF) (the “Company”) today announced that its Annual Meeting of shareholders and the Annual Meeting of voting policyholders of Sun Life Assurance Company of Canada scheduled for Wednesday, May 5, 2021 will be held in a virtual-only format. The Company also announced that its 2020 Annual Report and its Notice of Annual Meeting and Management Information Circular are now available.  

Virtual Annual Meetings of Shareholders and Voting Policyholders
At Sun Life, we’re in the business of helping our Clients achieve lifetime financial security and live healthier lives. The health and well-being of our employees, Clients, shareholders, policyholders and communities is our top priority. Sun Life is doing its part to help contain the spread of the COVID-19 virus by holding its annual meetings in a virtual-only format again this year.

Shareholders and voting policyholders will have the opportunity to attend the meeting online in real time regardless of their location, submit questions and vote on a number of important matters. Shareholders, voting policyholders, investors or members of the public will not be able to attend the meeting in person.

Sun Life’s virtual Annual Meeting will be held Wednesday, May 5, 2021 at 5 p.m. (Toronto time) by live webcast at https://web.lumiagm.com/447957232 using the password “sunlife2021” (case sensitive). For detailed instructions on how to join the webcast and vote at the virtual meeting, shareholders should refer to the 2021 Management Information Circular and voting policyholders should refer to the Information for Voting Policyholders’ Booklet and their proxy form or voting instruction form.

Shareholders and voting policyholders are encouraged to vote in advance by one of the methods described in the 2021 Management Information Circular or
Information for Voting Policyholders’ Booklet, as applicable
. Registered shareholders are asked to return their completed proxies or exercise their vote by the voting deadline on Monday, May 3, 2021 at 5 p.m. (Toronto time).
Voting policyholders are asked to return their proxies no later than 5 p.m. (Toronto time) on Wednesday, April 28, 2021.

If you have any questions, please call our transfer agent, AST Trust Company (Canada) at the following numbers:

Canada and the United States:

1-877-224-1760

United Kingdom, Republic of Ireland, Channel
Islands and Isle of Man:

+ 44 (0) 345-602-1587

Philippines:

632-5318-8567 (Metro Manila)

1-800-1-888-2422 (Provinces)

Hong Kong:

852-2862-8555

Other countries:

416-682-3865

Election of new Directors
 

The Management Information Circular includes the nominations of Deepak Chopra and David H. Y. Ho for election at the Annual Meeting to join the Company’s Board of Directors. 

Mr. Chopra is a corporate director and previously served as the President and Chief Executive Officer of Canada Post Corporation. He has more than 30 years of global experience in the financial services, technology, logistics and supply-chain industries. He currently sits on the boards of The Descartes Systems Group Inc., Celestica Inc., and The North West Company Inc. He is a Fellow of the Institute of Chartered Professional Accountants of Canada and holds a Bachelor’s degree in Commerce (Honours) and a Post Graduate Diploma in Business Management (PGDBM).

Mr. Ho is Chairman and Founder of Kiina Investment Limited, a venture capital firm that invests in start-up companies in the technology, media and telecommunications industries. He currently sits on the boards of Qorvo, Inc., Air Products & Chemicals, Inc., China COSCO Shipping Corporation, and DBS Bank (Hong Kong) Limited, a subsidiary of DBS Group Holdings. He holds a Bachelor of Applied Science (Honours Systems Design Engineering) and a Master of Applied Science in Management Sciences.

At the conclusion of the Annual Meeting, Sara Grootwassink Lewis and Hugh D. Segal will retire from the Board of Directors.

Meeting Materials
The meeting materials for Sun Life Financial Inc. have been filed with the Canadian securities regulators and the United States Securities and Exchange Commission. Distribution to shareholders began today and materials can also be accessed electronically on:
SEDAR at https://www.sedar.com
EDGAR at https://www.sec.gov/edgar.shtml 
Our transfer agent’s website at https://www.meetingdocuments.com/astca/slf  
Our website at www.sunlife.com/2021agm and www.sunlife.com/AnnualReport.

Shareholders may obtain printed copies of the audited annual financial statements free of charge by contacting the Company through its website.

The 2020 Annual Report includes the Company’s management’s discussion and analysis, consolidated financial statements, earnings by business group and other Company information.

The meeting materials for Sun Life Assurance Company of Canada can be accessed electronically on:
Our transfer agent’s website at https://www.meetingdocuments.com/astca/sla 
Our website at www.sunlife.com/2021agm and www.sunlife.com/AnnualReport.

2020 Sustainability Report
The Company’s 2020 Sustainability Report and Public Accountability Statement were also released today and can be accessed at www.sunlife.com/Sustainability.

About Sun Life
Sun Life is a leading international financial services organization providing insurance, wealth and asset management solutions to individual and corporate Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of December 31, 2020, Sun Life had total assets under management of C$1,247 billion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Media Relations Contact:

Investor Relations Contact:

Irene Poon

Leigh Chalmers

Manager

Senior Vice-President, Head of Investor

Corporate Communications   

Relations & Capital Management 

T.  416-988-0542               

T. 647-256-8201


[email protected]


[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/sun-life-announces-virtual-annual-meetings-of-shareholders-and-voting-policyholders-and-availability-of-2020-annual-report-2021-management-information-circular-and-2021-information-for-voting-policyholders-booklet-301256368.html

SOURCE Sun Life Financial Inc.

Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update

Clinical drug pipeline is funded and targeting major milestones in 2021

HANOVER, Md., March 25, 2021 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announces financial results for the year ended December 31, 2020, and provides corporate update.

Dr. David Young, CEO and chairman of Processa, commented, “2020 was a transformational year for our company; we in-licensed three exciting programs with potential markets exceeding $1 billion for each drug, improved our balance sheet, strengthened our management team and Board, up-listed to Nasdaq, and prepared the foundation for successful execution for our three clinical stage programs. I am delighted to report that we anticipate the first patients to be dosed with PCS6422 and PCS499 in the second quarter of 2021 with interim data for PCS6422 near the end of Q3 and for PCS499 in the first quarter of 2022.”

Recent Highlights and New Developments

  • Selected 5 U.S. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for our Phase 2B trial “A Randomized, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients who Have Necrobiosis Lipoidica.” Two to three additional clinical sites will be selected in the future including sites outside the U.S.
  • Entered into an exclusive licensing agreement with Elion Oncology, Inc. to develop, manufacture and commercialize PCS6422 (eniluracil) globally. PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs (e.g., capecitabine, 5-FU). PCS6422 is designed to decrease the breakdown of the cancer drugs, which, without such intervention, reduce to inactive metabolites or metabolites that are known to cause unwanted side effects and to interfere with the anticancer activity.
  • Entered into a licensing agreement with Yuhan Corporation, a publicly traded South Korean company, to license PCS12852, a small molecule drug in development for the treatment of gastroparesis and functional gastrointestinal motility disorders.
  • Entered into a licensing agreement with Aposense LTD to license PCS11T, a pro-drug of SN38, the active metabolite of the widely used cancer drug irinotecan, that deposits SN38 in the membranes of cancer cells preferentially over normal cells.
  • Appointed Dr. Khalid Islam to the Company’s board of directors.
  • Appointed Michael Floyd as the Company’s chief operating officer.
  • Uplisted to Nasdaq.
  • Closed an underwritten public offering of 4,800,000 shares of common stock for a price to the public of $4.00 per share with net proceeds of $17.1 million.
  • In February 2021 we closed a private placement with institutional and accredited investors for $10.2 million. We sold 1,321,132 shares of the common stock at a purchase price of $7.75 per share for $10.2 million in the private placement and received net proceeds of $9.9 million.

Upcoming Clinical Drug Development Milestones


First half of 2021

  • Phase 1B First Patient Dosed: PCS6422 (Cancer)
  • Phase 2 First Patient Dosed: PCS499 (Ulcerative NL)


Second half of 2021

  • FDA IND Submission: PCS12852 (GI/Gastroparesis)
  • Interim Cohort Results Begin: PCS6422


First half of 2022

• Interim Results: PCS499

• Phase 2A First Patient Dosed: PCS12852

Financial Results for the Year Ended December 31, 2020

General and administrative expenses were $3.3 million compared to $1.6 million for the year ended December 31, 2019. The increase in our general and administrative expenses was primarily due to stock-based compensation.

Research and development expenses totaled $3.2 million compared to $2.3 million for the year ended December 31, 2019.

We also recorded $8.7 million dollars of costs as the acquisition of in-process research and development related to licensing agreements we executed for PCS6422, PCS12852 and PCS11T. A total of $8.6 million of this amount was non-cash consideration.

Our net loss was $14.4 million, compared to a net loss of $3.4 million for the year ended December 31, 2019. During 2020 we recorded non-cash expenses of $8.6 million for acquired in-process research and development and $2.7 million of stock-based compensation costs.

As of December 31, 2020, the Company had cash and cash equivalents of $15.4. In February 2021, we closed a $10.2 million private placement receiving net proceeds of $9.9 million.

Following the close of the offering and related transactions the Company will have 15.5 million common shares outstanding.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: March 25, 2021
Time: 5:30 p.m. ET
Toll Free: 877-545-0320; Entry Code: 805295
International: 973-528-0016; Entry Code: 805295

Live Webcast: https://www.webcaster4.com/Webcast/Page/2572/40452

Conference Call Replay Information

Toll-free: 877-481-4010
International: 919-882-2331
Replay Passcode: 40452

About Processa Pharmaceuticals, Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com .

Forward-Looking Statements

This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements that involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements.

For More Information: 
Michael Floyd 
(301) 651-4256 
[email protected]

James Carbonara 
Hayden IR 
(646) 755-7412 
[email protected]



Crestwood Equity Partners LP Announces Strategic Transactions with Crestwood Holdings and Provides Update to 2021 Strategic Outlook

Crestwood Equity Partners LP Announces Strategic Transactions with Crestwood Holdings and Provides Update to 2021 Strategic Outlook

Crestwood and First Reserve have agreed to a series of transactions that provide First Reserve a complete exit from its investment in Crestwood Equity Partners LP, transferring control of the general partner interest to Crestwood and transitioning Crestwood to a publicly elected board of directors in accordance with ESG strategy

Transaction results in greater than 15% accretion to distributable cash flow per unit, increased free cash flow, larger public trading float and enhanced credit profile

Strong performance year-to-date and favorable full-year 2021 outlook drive an increased full-year 2021 Adjusted EBITDA estimate of $575 million to $625 million

HOUSTON–(BUSINESS WIRE)–
Crestwood Equity Partners LP (NYSE: CEQP) (“Crestwood”) today announced that it and Crestwood Holdings LLC (“Crestwood Holdings”) have executed a series of definitive agreements whereby Crestwood will acquire approximately 11.5 million common units and the general partner interest from Crestwood Holdings for total consideration of approximately $268 million. In addition, in a separate press release issued today, Crestwood announced that First Reserve priced a private placement of six million common units for total proceeds of $132 million. With the combination of these transactions, First Reserve expects to have fully exited its investment in Crestwood. Crestwood will retire the approximate 11.5 million outstanding common units currently held by First Reserve, and transition to a publicly elected Board of Directors. Additionally, the Board of Directors has authorized a $175 million opportunistic common and preferred unit repurchase program.

Highlights of the Transactions and Updated Strategic Initiatives:

  • Enhanced corporate governance: Thetransactions enable the implementation of a traditional public company governance structure with a publicly elected board of directors further ensuring alignment between management and the Board of Directors with common unitholders, consistent with Crestwood’s long-term ESG strategy.
  • Significantly accretive: Distributable cash flow per unit metrics are significantly enhanced with the buyback and retirement of approximately 11.5 million common units, or approximately 15% of total common units outstanding, resulting in annual common distribution savings of approximately $29 million based on the current annual rate of $2.50 per common unit.
  • Larger and more diversified investor base: Thetransactionsand related dispositions of Crestwood common units by First Reserve are expected to result in theincrease of Crestwood’s public trading float by approximately 12% with more diverse institutional ownership and allow First Reserve to exit its large block ownership position of approximately 24% of total common units outstanding in Crestwood in a strategic and well executed manner.
  • Credit enhancing: The transactions improve Crestwood’s outlook with the rating agencies with the complete repayment of the Term Loan B at Crestwood Holdings and improve Crestwood’s consolidated capital structure under the agencies’ methodology.
  • Unit Repurchase Program: In connection with the transactions and enhancements to Crestwood’s future governance structure and investor alignment, Crestwood’s Board of Directors has also approved a $175 million common unit and preferred unit repurchase program effective through December 31, 2022.

“Today marks a great milestone in the history of Crestwood with the buy-in of First Reserve’s interest in a transaction that enhances our alignment with common unitholders, improves our financial flexibility, and advances our strategic objectives to be a best-in-class midstream infrastructure company and maximize returns to our unitholders,” stated Robert G. Phillips, Chairman, President and Chief Executive Officer of Crestwood’s general partner. “I would like to thank the First Reserve organization for their support, guidance and partnership over the last ten years as they helped us tremendously to build Crestwood into a premier midstream company. Crestwood has established a track record of solid execution, disciplined capital allocation and a commitment to embracing a best-in-class MLP sustainability program. Today’s announcements are the next logical steps in our strategy to drive peer leading governance and set the stage for future growth by simplifying our organizational structure, increasing our public float and liquidity, and enhancing our financial flexibility as we strive to generate long-term value for our unitholders.”

Gary D. Reaves, Managing Director of First Reserve said, “First Reserve would like to thank the Crestwood organization for its partnership over the past ten years. While today marks the culmination of over a decade of First Reserve’s ownership of Crestwood, we will certainly maintain our long-standing relationships with the Crestwood team and all Crestwood stakeholders, and we exit this investment proud of all that Crestwood has achieved in the past decade including its leadership role in MLP sustainability initiatives. We continue to believe the outlook is bright for the Crestwood organization and look forward to watching its future success in the years to come.”

Transaction Details

Under the terms of the transactions, First Reserve will exit its investment in Crestwood which included 17.5 million common units, approximately 24% of total common units outstanding, and control of the general partner. In a series of transactions, First Reserve has entered into agreements with third parties to sell six million common units representing limited partner interests in Crestwood, with expected total proceeds of $132 million. In addition, Crestwood expects to repurchase the general partner interest and the remaining 11.5 million units held by First Reserve with $268 million drawn on its existing $1.25 billion revolving credit facility.

Following completion of the transactions, Crestwood will have approximately 62.8 million common units outstanding, representing an approximate 15% reduction in total common unit count. Crestwood’s buyback of First Reserve’s common units results in annual cash distribution savings of approximately $29 million based on the current annual distribution rate of $2.50 per common unit. The closing of the repurchase of First Reserve’s common units is expected to occur on March 30, 2021 and the closing of the acquisition of the general partner interest is expected to occur in the coming months and is not subject to any closing conditions.

The transactions between Crestwood and First Reserve were unanimously approved by the Conflicts Committee of the Board of Directors of the general partner of Crestwood following review with legal counsel Akin Gump Strauss Hauer & Feld LLP and rendering of a fairness opinion to the Conflicts Committee from Evercore. Following the approval by the Conflicts Committee, these transactions were unanimously approved by the Board of Directors of the general partner, with First Reserve affiliated directors abstaining.

Today’s announcement does not affect Crestwood’s nor First Reserve’s ownership in Crestwood Permian Basin Holdings LLC (“CPJV”). CPJV was formed in November 2016 to develop, own, and operate vital midstream infrastructure assets in the Delaware Basin and is held in a separate 10-year fund that First Reserve formed in 2014.

Crestwood to Transition to an Elected Board

Gary D. Reaves and William R. Brown will resign from the Board of Directors at closing of the initial transaction, which is scheduled for March 30, 2021. Going forward, to enhance its corporate governance sustainability initiatives, Crestwood will transition to a fully elected board with traditional public company oversight that includes a staggered board feature, term limits, and a continued commitment to board diversity. Crestwood will maintain a board composed of seven directors until such time as it can appoint two independent replacements.

Revised 2021 Outlook

Based on preliminary results, Crestwood estimates it will exceed its first quarter 2021 budget as a result of outperformance driven by stronger than expected commodity prices. Based on Crestwood’s preliminary first quarter 2021 results, today’s announced transactions, and a favorable commodity price outlook for the remainder of 2021, Crestwood is revising its full-year financial outlook as it no longer expects the previous Adjusted EBITDA range of $550 million to $610 million to accurately reflect business performance in 2021.These projections are subject to risks and uncertainties as described in the “Forward-Looking Statements” section at the end of this release.

  • Net income of $100 million to $150 million
  • Adjusted EBITDA of $575 million to $625 million
  • Contribution by operating segment is set forth below:

$US millions

 

Adj. EBITDA Range

Operating Segment

 

Low

 

High

Gathering & Processing

 

$450

$490

Storage & Transportation

 

80

85

Marketing, Supply & Logistics

 

100

105

Less: Corporate G&A

 

(55)

 

(55)

FY 2021 Totals

 

$575

$625

  • Distributable cash flow available to common unitholders of $335 million to $385 million
  • Free cash flow after distributions of $130 million to $180 million
  • Full-year 2021 coverage ratio expected to be greater than 2.00x
  • Full-year 2021 leverage ratio expected to be lower than 4.25x
  • Growth project capital and joint venture contributions and maintenance capital spending remain unchanged in the range of $35 million to $45 million and $20 million to $25 million, respectively

Common and Preferred Unit Repurchase Program

Crestwood announced that its Board of Directors has authorized a $175 million common unit and preferred unit repurchase program effective immediately through December 31, 2022. This program is intended to supplement the company’s deleveraging goals and utilize additional free cash flow to optimize its long-term cost of capital and generate value for common unitholders. Crestwood plans to continue to prioritize its capital allocation strategies towards first achieving its long-term leverage target of 3.5x to 4.0x, but believes that the unit repurchase program is an incremental tool that can be used for allocation of strong free cash flow generation going forward to accomplish its chief objective of maximizing value for its investors. Crestwood may purchase common and preferred units from time to time in the open market in accordance with applicable securities laws at current market prices, in privately negotiated transactions or pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934. The timing and amount of purchases under the program will be determined based on ongoing assessments of leverage goals, growth capital opportunities, financial performance and outlook, and other factors, including acquisition opportunities and market conditions. The unit repurchase program does not obligate Crestwood to purchase any specific dollar amount or number of units and may be suspended or discontinued at any time.

Advisors

Citi served as Crestwood’s financial advisor and Hunton Andrews Kurth LLP and Vinson & Elkins LLP served as legal advisors. Evercore served as financial advisor to Crestwood’s Conflicts Committee and Akin Gump Strauss Hauer & Feld LLP served as legal advisor. Simpson Thacher & Bartlett LLP served as legal advisor to First Reserve. Baker Botts L.L.P. served as legal advisor to Citi.

Non-GAAP Financial Measures

Adjusted EBITDA, distributable cash flow and free cash flow are non-GAAP financial measures. The accompanying schedules of this news release provide reconciliations of these non-GAAP financial measures to their most directly comparable financial measures calculated and presented in accordance with GAAP. Our non-GAAP financial measures should not be considered as alternatives to GAAP measures such as net income or operating income or any other GAAP measure of liquidity or financial performance.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities and Exchange Act of 1934. The words “expects,” “believes,” “anticipates,” “plans,” “will,” “shall,” “estimates,” and similar expressions identify forward-looking statements, which are generally not historical in nature. Forward-looking statements, including statements regarding our revised 2021 outlook, are subject to risks and uncertainties and are based on the beliefs and assumptions of management, based on information currently available to them. Although Crestwood believes that these forward-looking statements are based on reasonable assumptions, it can give no assurance that any such forward-looking statements will materialize. Important factors that could cause actual results to differ materially from those expressed in or implied from these forward-looking statements include the risks and uncertainties described in Crestwood’s reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its subsequent reports, which are available through the SEC’s EDGAR system at www.sec.gov and on our website. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect management’s view only as of the date made, and Crestwood assumes no obligation to update these forward-looking statements.

About First Reserve

First Reserve is a leading global private equity investment firm exclusively focused on energy, including related industrial markets. With over 35 years of industry insight, investment expertise and operational excellence, the firm has cultivated an enduring network of global relationships and raised more than $32 billion of aggregate capital since inception. First Reserve has completed approximately 700 transactions (including platform investments and add-on acquisitions), creating several notable energy companies throughout the firm’s history. Its portfolio companies have operated on six continents, spanning the energy spectrum from upstream oil and gas to midstream and downstream, including resources, equipment and services, and associated infrastructure. Please visit www.firstreserve.com for further information.

About Crestwood Equity Partners LP

Houston, Texas, based Crestwood Equity Partners LP (NYSE: CEQP) is a master limited partnership that owns and operates midstream businesses in multiple shale resource plays across the United States. Crestwood Equity is engaged in the gathering, processing, treating, compression, storage and transportation of natural gas; storage, transportation, terminalling and marketing of NGLs; gathering, storage, terminalling and marketing of crude oil; and gathering and disposal of produced water. Visit Crestwood Equity Partners LP at www.crestwoodlp.com; and to learn more about Crestwood’s sustainability efforts, please visit https://esg.crestwoodlp.com.

CRESTWOOD EQUITY PARTNERS LP

Full Year 2021 Adjusted EBITDA, Distributable Cash Flow and Free Cash Flow Guidance

Reconciliation of Non-GAAP Financial Measures

(in millions)

(unaudited)

 

Expected 2021 Range

 

Low – High

Net Income Reconciliation

 

Net income (b)

$100 – $150

Interest and debt expense, net (a)

160 – 165

Depreciation, amortization and accretion

235 – 240

Unit-based compensation charges

25 – 30

Earnings from unconsolidated affiliates (b)

(40) – (45)

Adjusted EBITDA from unconsolidated affiliates

85 – 90

Adjusted EBITDA

$575 – $625

 

 

Cash interest expense (c)

(145) – (150)

Maintenance capital expenditures (d)

(20) – (25)

PRB cash received in excess of recognized revenues (e)

25 – 30

Adjusted EBITDA from unconsolidated affiliates

(85) – (90)

Distributable cash flow from unconsolidated affiliates

80 – 85

Cash distributions to preferred unitholders (f)

(100)

Distributable cash flow attributable to CEQP (g)

$335 – $385

Cash Flows from Operating Activities Reconciliation

 

Net cash provided by operating activities, net

$410 – $460

Interest and debt expense, net (a)

160 – 165

Adjusted EBITDA from unconsolidated affiliates

85 – 90

Earnings from unconsolidated affiliates (b)

(40) – (45)

Amortization of debt-related deferred costs

(5) – (10)

Changes in operating assets and liabilities, net

(35) – (40)

Adjusted EBITDA

$575 – $625

 

 

Cash interest expense (c)

(145) – (150)

Maintenance capital expenditures (d)

(20) – (25)

PRB cash received in excess of recognized revenues (e)

25 – 30

Adjusted EBITDA from unconsolidated affiliates

(85) – (90)

Distributable cash flow from unconsolidated affiliates

80 – 85

Cash distributions to preferred unitholders (f)

(100)

Distributable cash flow attributable to CEQP (g)

$335 – $385

 

 

Less: Growth capital expenditures

35 – 45

Less: Distributions to common unitholders

165

Free cash flow after distributions (h)

$130 – $180

  1. Includes gain (loss) on modification/extinguishment of debt, net
  2. Does not include any potential impact on our earnings from unconsolidated affiliates related to Consolidated Edison, Inc.’s evaluation of strategic alternatives with respect to our Stagecoach Gas Services LLC equity investment.
  3. Cash interest expense less amortization of deferred financing costs.
  4. Maintenance capital expenditures are defined as those capital expenditures which do not increase operating capacity or revenues from existing levels.
  5. Cash received from customers of our Powder River Basin operations pursuant to certain contractual minimum revenue commitments in excess of related revenue recognized under FASB ASC 606.
  6. Includes cash distributions to preferred unitholders and Crestwood Niobrara preferred unitholders.
  7. Distributable cash flow is defined as Adjusted EBITDA, adjusted for cash interest expense, maintenance capital expenditures, income taxes, the cash received from our Powder River Basin operations in excess of revenue recognized, and our proportionate share of our unconsolidated affiliates’ distributable cash flow. Distributable cash flow should not be considered an alternative to cash flows from operating activities or any other measure of financial performance calculated in accordance with generally accepted accounting principles as those items are used to measure operating performance, liquidity, or the ability to service debt obligations. We believe that distributable cash flow provides additional information for evaluating our ability to declare and pay distributions to unitholders. Distributable cash flow, as we define it, may not be comparable to distributable cash flow or similarly titled measures used by other companies.
  8. Free cash flow after distributions is defined as distributable cash flow attributable to common unitholders less growth capital expenditures and distributions to common unitholders. Free cash flow after distributions should not be considered an alternative to cash flows from operating activities or any other measure of liquidity calculated in accordance with generally accepted accounting principles as those items are used to measure liquidity or the ability to service debt obligations. We believe that free cash flow after distributions provides additional information for evaluating our ability to generate cash flow after paying our distributions to common unitholders and paying for our growth capital expenditures.

 

Crestwood Equity Partners LP

Investor Contacts

Josh Wannarka, 713-380-3081

[email protected]

Senior Vice President, Investor Relations, ESG & Corporate Communications

Rhianna Disch, 713-380-3006

[email protected]

Director, Investor Relations

Sustainability and Media Contact

Joanne Howard, 832-519-2211

[email protected]

Vice President, Sustainability and Corporate Communications

KEYWORDS: Texas Kansas United States North America

INDUSTRY KEYWORDS: Oil/Gas Alternative Energy Energy Other Energy Utilities

MEDIA:

Logo
Logo

HireQuest Reports Financial Results for the Fourth Quarter and Full-Year 2020

HireQuest Reports Financial Results for the Fourth Quarter and Full-Year 2020

Full-Year EPS of $0.39 per Diluted Share and Cash Flow of More than $9 Million;

Scaling Profitable Business Model – Adding 67 New Franchised Locations and 10 Licensed Locations Through Accretive Acquisitions

GOOSE CREEK, S.C.–(BUSINESS WIRE)–
HireQuest, Inc. (Nasdaq: HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today reported financial results for the fourth quarter and year ended December 31, 2020.

Full-Year 2020 Financial Summary

  • Franchise royalties of $12.8 million compared to $14.7 million in the prior year, a decrease of 12.8%.
  • Services revenue, including interest paid on aging accounts receivable, of $1.0 million compared to $1.2 million in the prior year, a decrease of 15.5%.
  • Total revenue of $13.8 million compared to $15.9 million in the prior year, a decrease of 13.0%.
  • Net Income was $5.4 million, or $0.39 per diluted share, compared to a net loss of $290,000, or $(0.03) per share last year.

Subsequent to Year End

  • Board of Directors declared a quarterly cash dividend of $0.05 per share of common stock to be paid on March 15, 2021 to shareholders of record as of March 1, 2021. The company intends to pay quarterly cash dividends on its common stock each year in March, June, September and December, subject to final approval by the Board of Directors each quarter after its review of the Company’s financial performance each quarter.
  • Completed the acquisition of certain assets of Snelling Staffing for approximately $17.3 million, before working capital adjustments.
  • Acquired the franchised operations of LINK Staffing for approximately $11.1 million exclusive of working capital.

Fourth Quarter 2020 Financial Summary

  • Franchise royalties of $3.2 million compared to $5.4 million in the prior year period, a decrease of 40.2%.
  • Services revenue, including interest paid on aging accounts receivable, of $176,000 compared to $476,000 in the prior year period, a decrease of 63.0%.
  • Total revenue of $3.4 million compared to $5.9 million in the prior year period, a decrease of 42.0%.
  • Net Income was $1.4 million, or $0.10 per diluted share, compared to net income of $3.5 million, or $0.26 per share last year.
  • Paid quarterly cash dividend of $0.05 per share.

System-wide sales1 for 2020 were $210.9 million compared to $241.6 million for 2019. For the fourth quarter of 2020, system-wide sales1 were $54.8 million. The decrease is related to the economic slowdown due to COVID-19.

“As a result, we have been able to leverage the advantages of our business model and our balance sheet to grow our business through strategic acquisitions,” added Mr. Hermanns. “We recently closed the acquisition of Snelling Staffing, adding 38 franchised locations, 4 licensed locations, and integrating the 70-year-old tradename of Snelling. We also closed the acquisition of LINK Staffing, adding another 29 franchised and 6 licensed locations. In the aggregate, these two acquisitions add substantial scale. These franchised and licensed locations accounted for $133 million in system-wide sales in 2020 and meaningfully expand our national presence. Additionally, both Snelling and LINK specialize in traditional commercial staffing, giving us a second lucrative franchising revenue stream. Going forward, we will be able to sell franchises for both on-demand and commercial staffing models, while maintaining significant scale to create operational efficiency and facilitating the acquisition of national accounts to support our franchisees.”

“To further mitigate risk and take advantage of our scale, we divested the licensed locations, all in California, to a third party who has agreed to pay a perpetual royalty fee for the use of the Snelling and LINK trademarks,” added Mr. Hermanns. “Between this transaction, the sale of certain branches, the sale of $5.3 million of notes receivable, and the cash flow generated by these acquisitions, we have paid off our line of credit and are in a net cash-positive position again. Most importantly the company is well positioned to benefit from a post-pandemic return to economic normalcy. When that happens, and we don’t know when, we should experience tremendous earnings leverage with our expanded platform.”

“To further mitigate risk and take advantage of our scale, we divested four California locations acquired from Snelling and six locations acquired from Link to a third party who has agreed to pay a perpetual royalty fee to HireQuest for the use of the Snelling trademark,” added Mr. Hermanns. “Between this transaction, the sale of certain branches, the sale of $5.3 million of notes receivable, and the cash flow generated by these acquisitions, we have paid off our line of credit and are in a net cash-positive position again. Most importantly the company is well positioned to benefit from a post-pandemic return to economic normalcy. When that happens, and we don’t know when, we should experience tremendous earnings leverage with our expanded platform.”

Fourth Quarter 2020 Financial Results

The company’s total revenue is calculated by aggregating its revenue derived from franchise royalties and service revenue. Franchise royalties are the royalties earned from franchisees primarily on the basis of their sales to their customers. Service revenue consists of interest charged to franchisees on overdue accounts and other fees for optional services we provide our franchisees.

Franchise royalties in the fourth quarter of 2020 were $3.2 million compared to $5.4 million in the year-ago quarter, a decrease of 40.2%. Service revenue was $176,000 compared to $476,000 in the prior-year quarter, a decrease of 63.0%. Total revenue in the fourth quarter of 2020 was $3.4 million compared to $5.9 million in the year-ago quarter, a decrease of 42.0%.

Selling, general and administrative (“SG&A”) expenses in the fourth quarter of 2020 were $2.2 million compared to $3.1 million for the fourth quarter last year. The fourth quarter of 2019 included approximately $0.5 million of non-recurring, merger-related expenses. The decrease in SG&A was also driven by a decrease in expenses related to workers’ compensation costs and bad debt.

Net Income in the fourth quarter of 2020 was $1.4 million, or $0.10 per diluted share, compared to net income of $3.5 million, or $0.26 per diluted share, in the fourth quarter last year (excluding a loss of $315,000, or $(0.02) per diluted share, in discontinued operations. The fourth quarter of 2020 did not include any discontinued operations.

___________________________

1 Refer to “Supplemental Operating Metrics” section at the end of this press release for a definition and additional details regarding System-wide sales

2 Based on a closing stock price of $10.12 on December 15, 2020

Full Year 2020 Financial Results

Franchise royalties for the full year 2020 were $12.8 million compared to $14.7 million in the prior year, a decrease of 12.8%. Service revenue was $1.0 million compared to $1.2 million in the prior year, a decrease of 15.5%.

Total revenue for the full year 2020 was $13.8 million compared to $15.9 million in the prior year, a decrease of 13.0%. This decrease is primarily due to the economic shutdown caused by COVID-19.

Selling, general and administrative (“SG&A”) expenses for the full year 2020 were $8.7 million compared to $12.7 million for the prior year, a decrease of 31.5%. The decrease in SG&A was primarily due to the absence of merger-related expenses in 2020. 2019 included approximately $5.1 million of non-recurring, merger-related expenses. The decrease was partially offset by an increase in stock-based compensation and a reserve placed on notes receivable that the company issued to finance the sale of offices acquired in its merger in 2019. This reserve is directly related to the negative impact COVID-19 has had on the economy, the financial condition of the company’s borrowers and the value of the underlying collateral.

Net Income for the full year 2020 was $5.4 million, or $0.39 per diluted share, compared to a net loss of $290,000, or $(0.03) per diluted share, in the prior year. In 2019, the net loss from continuing operations, which excluded discontinued operations, was $505,000, or $(0.05) per diluted share. 2020 did not include any discontinued operations.

Balance Sheet and Capital Structure

Cash was $13.7 million as of December 31, 2020, compared to $4.2 million as of December 31, 2019.

Total assets were $49.1 million as of December 31, 2020, and total liabilities were $12.7 million.

On December 15, 2020, the company paid a quarterly cash dividend of $0.05 per share of common stock to shareholders of record as of December 1, 2020. The company intends to pay a $0.05 cash dividend on a quarterly basis, based on its business results and financial position.

Conference Call

HireQuest will hold a conference call to discuss its financial results.

Date:

Thursday, March 25, 2021

Time:

4:30 p.m. Eastern time (2:30 p.m. Mountain time)

Toll-free dial-in number:

1-877-545-0320

International dial-in number:

1-973-528-0016

Entry Code:

904518

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

The conference call will be broadcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2359/40349 and via the investor relations section of HireQuest’s website at www.hirequest.com.

A replay of the conference call will be available through April 8, 2021.

Toll-free replay number:

1-877-481-4010

International replay number:

1-919-882-2331

Replay Passcode:

40349

About HireQuest

HireQuest, Inc. is a nationwide franchisor that provides on-demand labor and commercial staffing solutions in the light industrial, blue-collar, and commercial segments of the staffing industry for HireQuest Direct, HireQuest, Snelling, and LINK franchised offices across the United States. Through its national network of over 200 franchisee-owned offices in more than 35 states and the District of Columbia, HireQuest provides employment for approximately 60,000 individuals annually that work for thousands of customers in numerous industries including construction, light industrial, manufacturing, hospitality, clerical, medical, travel, and event services. For more information, visit www.hirequest.com.

Important Cautions Regarding Forward-Looking Statements

This news release includes, and the company’s officers and other representatives may sometimes make or provide certain estimates and other forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act, including, among others, statements with respect to future revenue, franchise sales, system-wide sales, and the growth thereof; operating results; anticipated benefits of the acquisition of Snelling and/or LINK., or the conversion of Snelling’s corporate offices to the franchise model; intended office openings; expectations of the effect on our financial condition of claims and litigation; strategies for customer retention and growth; strategies for risk management; and all other statements that are not purely historical and that may constitute statements of future expectations. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods.

While the company believes these statements are accurate, forward-looking statements are not historical facts and are inherently uncertain. They are based only on the company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. The company cannot assure you that these expectations will occur, and its actual results may be significantly different. Therefore, you should not place undue reliance on these forward-looking statements. Important factors that may cause actual results to differ materially from those contemplated in any forward-looking statements made by the company include the following: the level of demand and financial performance of the temporary staffing industry; the financial performance of the company’s franchisees; changes in customer demand; the effects of any global pandemic including the impact of the novel coronavirus disease (“COVID-19”); the extent to which the company is successful in gaining new long-term relationships with customers or retaining existing ones, and the level of service failures that could lead customers to use competitors’ services; significant investigative or legal proceedings including, without limitation, those brought about by the existing regulatory environment or changes in the regulations governing the temporary staffing industry and those arising from the action or inaction of the company’s franchisees and temporary employees; strategic actions, including acquisitions and dispositions and the company’s success in integrating acquired businesses including, without limitation, successful integration following the acquisitions of Snelling and LINK; disruptions to the company’s technology network including computer systems and software; natural events such as severe weather, fires, floods, and earthquakes, or man-made or other disruptions of the company’s operating systems; and the factors discussed in the “Risk Factors” section and elsewhere in the company’s most recent Annual Report on Form 10-K.

Any forward-looking statement made by the company or its management in this news release is based only on information currently available to the company and speaks only as of the date on which it is made. The company and its management disclaim any obligation to update or revise any forward-looking statement, whether written or oral, that may be made from time to time, based on the occurrence of future events, the receipt of new information, or otherwise, except as required by law.

HireQuest, Inc.

Consolidated Balance Sheets

 

December 31,

2020

December 31,

2019

ASSETS

 

 

Current assets

Cash

$ 13,667,434

 

$ 4,187,450

Accounts receivable, net of allowance for doubtful accounts

21,344,499

28,201,279

Notes receivable

2,178,299

 

3,419,458

Prepaid expenses, deposits, and other assets

344,091

188,560

Prepaid workers’ compensation

1,434,583

 

822,938

Other assets

201,440

Total current assets

38,968,906

 

37,021,125

Property and equipment, net

3,193,379

1,900,686

Deferred tax asset

79,379

 

Intangible assets, net

342,697

Notes receivable, net of current portion and reserve

5,887,229

 

7,990,251

Total assets

$ 49,095,042

$ 46,912,062

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities

Accounts payable

$ 457,490

 

$ 253,845

Other current liabilities

1,322,764

1,893,846

Accrued benefits and payroll taxes

743,431

 

1,113,904

Due to affiliates

67,398

Due to franchisees

3,228,777

 

3,610,596

Risk management incentive program liability

858,482

1,811,917

Workers’ compensation claims liability

2,777,734

 

2,327,869

Total current liabilities

9,456,076

 

11,011,977

Workers’ compensation claims liability, net of current portion

1,806,334

1,516,633

Franchisee deposits

1,468,359

 

1,412,924

Deferred tax liability

1,688,446

Total liabilities

12,730,769

 

15,629,980

Commitments and contingencies

Stockholders’ equity

 

 

 

Preferred stock – $0.001 par value, 1,000,000 shares authorized; none issued

Common stock – $0.001 par value, 30,000,000 shares authorized; 13,628,675 and 13,518,036 shares issued, respectively

13,629

 

13,518

Additional paid-in capital

28,811,389

27,584,610

Treasury stock, at cost – 33,092 and -0- shares, respectively

(146,465)

 

Retained earnings

7,685,720

3,683,954

Total stockholders’ equity

36,364,273

 

31,282,082

Total liabilities and stockholders’ equity

$ 49,095,042

$ 46,912,062

HireQuest, Inc.

Consolidated Statements of Income

Three months ended

Year ended

 

December 31, 2020

December 31, 2019

December 31, 2020

December 31, 2019

(unaudited)

(unaudited)

Franchise royalties

$ 3,229,658

 

$ 5,396,922

 

$ 12,792,793

 

$ 14,673,636

Service revenue

175,817

475,748

1,016,332

1,202,824

Total revenue

3,405,475

 

5,872,670

 

13,809,125

 

15,876,460

Selling, general and administrative expenses

2,158,276

 

3,131,312

 

8,700,446

 

12,692,297

Depreciation and amortization

32,528

 

324,502

 

129,182

 

400,132

Income (loss) from operations

1,214,671

2,416,856

4,979,497

2,784,031

Other miscellaneous income

238,365

 

(616)

 

1,170,619

 

751,077

Interest and other financing expense

(10,490)

(37,748)

(49,664)

(559,585)

Net income before income taxes

1,442,546

 

2,378,492

 

6,100,452

 

2,975,523

Provision (benefit) for income taxes

86,446

 

(1,399,406)

 

741,038

 

3,480,996

Income (loss) from continuing operations

1,356,100

 

3,777,898

 

5,359,414

 

(505,473)

Income from discontinued operations, net of tax

(315,067)

215,494

Net income (loss)

$ 1,356,100

 

$ 3,462,831

 

$ 5,359,414

 

$ (289,979)

 

Basic earnings per share

 

 

 

 

 

 

 

Continuing operations

$ 0.10

$ 0.28

$ 0.40

$ (0.05)

Discontinued operations

 

(0.02)

 

 

0.02

Total

$ 0.10

$ 0.26

$ 0.40

$ (0.03)

 

 

 

 

 

 

 

 

Diluted earnings per share

Continuing operations

$ 0.10

 

$ 0.28

 

$ 0.39

 

$ (0.04)

Discontinued operations

(0.02)

0.02

Total

$ 0.10

 

$ 0.26

 

$ 0.39

 

$ (0.03)

 

Weighted average shares outstanding

 

 

 

 

 

 

 

Basic

13,589,006

13,488,436

13,542,403

11,588,776

Diluted

13,731,644

 

13,490,636

 

13,654,128

 

11,588,776

HireQuest, Inc.

Supplemental Operating Metrics

1 Management sometimes refers to total sales generated by its franchisees as “franchise sales.” Management also sometimes refers to sales at offices that were owned and operated by the company, not by one of its franchisees, as “company-owned sales,” all of which were sold as of September 29, 2019. Sales at company-owned offices are reflected net of costs, expenses, and taxes associated with those sales on the company’s financial statements as “Income from discontinued operations, net of tax.” The sum of franchise sales and company-owned sales is referred to as “system-wide sales,” a non-GAAP operating performance metric. In other words, system-wide sales include sales at all offices, whether owned and operated by the company or by its franchisees. While the company does not record franchise sales as revenue, management believes that information on system-wide sales is important to understanding the company’s financial performance because those sales are the basis on which the company calculates and records franchise royalty revenue, are directly related to interest charged on overdue accounts, which the company records under service revenue, and are indicative of the financial health of the franchisee base.

Company Contact:

HireQuest, Inc.

Cory Smith, CFO

(800) 835-6755

Email: [email protected]

Investor Relations Contact:

Hayden IR

Brett Maas

(646) 536-7331

Email: [email protected]

KEYWORDS: South Carolina United States North America

INDUSTRY KEYWORDS: Professional Services Human Resources

MEDIA:

SenesTech Announces Year End 2020 Financial and Operational Results

PR Newswire

PHOENIX, March 25, 2021 /PRNewswire/ — SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary, next generation technologies for managing animal pest populations through fertility control, today announced financial and operational results for the fourth quarter and fiscal year 2020, which ended on December 31, 2020.

Ken Siegel, CEO of SenesTech, commented, “We made significant progress in 2020 in building awareness and adoption of ContraPest, as evidenced by a 97% year-over-year increase in revenue. Although the revenue increase is from a relatively small base, we are making measurable progress despite the continuing pandemic. Importantly, we recently concluded pivotal ContraPest monitored deployments in agricultural and urban settings within integrated pest management programs initially including conventional rodenticides. The deployments had extremely positive results in reducing rat infestations and their enormous economic impact.  In addition to these pivotal deployments, the state of California has enacted legislation that went into effect January 1, 2021 that prohibits the use of the four major Second Generation Anticoagulant Rodenticides (SGARs) broadly used in traditional rodent pest control practices. As impacts from the pandemic begin to subside and we are able to more aggressively interact with potential agricultural and municipal customers, we believe we are well positioned to address these very large market opportunities.”

“Operationally, we have taken significant steps to better position SenesTech for the future. We have driven efficiencies in our operating structure which significantly reduces our breakeven point, including completing the move from Flagstaff to Phoenix. We are utilizing cash more effectively at approximately $1.6 million for the fourth quarter of 2020, and we completed a $10 million private placement in February 2021. I believe we are in the best position we have ever been to successfully address the enormous potential of ContraPest.”

Fourth Quarter and Fiscal 2020 Highlights

  • Revenue during 2020 was approximately $282,000 compared to approximately $143,000 in 2019, an increase of 97%.
  • Completed model agricultural deployments of ContraPest® with demonstrated, sustained success in reducing rat populations and improving operating economics in poultry settings. Results from both an egg production farm and a pullet house showed a 50% reduction in rats within six months of deployment and continued success as treatment progressed. The egg farm had a confirmed 90% decline in rat activity within 12 months of adding ContraPest. The pullet farm reported an 88% improvement in pullet survival after reducing their rat population with ContraPest. The projected incremental economic benefit of adding ContraPest to the pullet farm’s pest management plan resulted in over $600,000 in increased revenue and decreased costs.
  • Completed a long term monitored deployment of ContraPest® in a large, east coast urban setting within integrated pest management with conventional rodenticides, with demonstrated, sustained success in reducing rat populations. Data collected at month 12 from cameras showed that Site A had a 94% reduction in rat activity and a 98% decline in juvenile rat sightings since the start of monitoring. Site B had a 99% reduction in rat activity and 100% decline in juvenile rat sightings during the same period. These results showed that the ContraPest pilot was efficacious at lowering the rat populations and limiting the number of juveniles born, thus enhancing the results of the city’s rodent control program.
  • California’s AB1788 was signed by California’s Governor and became law January 1, 2021. The California Ecosystems Protection Act of 2020 will prohibit the use of the four major Second Generation Anticoagulant Rodenticides (SGARs) commonly used in rodent pest control under many circumstances, which opens up a potential $100 million annual market opportunity to alternative solutions, which includes ContraPest.
  • Completion of the move of all operations from Flagstaff to Phoenix, and the resumption of normal commercial production.
  • On a GAAP basis, net loss for 2020 was $(8.4) million, compared with a net loss of $(10.0) million for 2019.
  • Adjusted EBITDA loss, which is a non-GAAP measure of operating performance, for 2020 was $(6.9) million versus $(8.2) million in 2019.
  • In February 2021, the Company closed a private placement priced at-the-market under Nasdaq rules and resulted in net proceeds of approximately $9.2 million after the deduction of placement agent fees and expenses and estimated offering expenses payable by the Company.
  • In March 2021, the Company closed a shelf offering priced at-the-market under Nasdaq rules and resulted in net proceeds of $3.5 million after the deduction of placement agent fees and expenses and estimated offering expenses payable by the Company. We also had warrants exercised for an additional $1.2 million in cash.
  • Cash at the end of 2020, together with the proceeds of the private placement, the shelf, and the warrant exercises, was approximately $17.5 million.

Use of Non-GAAP Measure

Adjusted EBITDA is a non-GAAP measure. However, this measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar term. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.

Conference Call Details

Date and Time: Thursday, March 25, 2021 at 5:00 pm ET

Call-in Information: Interested parties can access the conference call by dialing (844) 308-3351 or (412) 317-5407.

Live Webcast Information: Interested parties can access the conference call via a live Internet webcast, which is available in the Investor Relations section of the Company’s website at http://senestech.investorroom.com/.

Replay: A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation #10153336. A webcast replay will be available in the Investor Relations section of the Company’s website at http://senestech.investorroom.com/ for 90 days. 

About SenesTech

SenesTech is changing the model for pest management by targeting one of the root causes of the problem: reproduction.

ContraPest® is an innovative technology with an approach that targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest® is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest® is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly.

We believe ContraPest® will establish a new paradigm in rodent control, resulting in a decreased reliance on lethal options. For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement

The foregoing paragraphs contain forward-looking statements that involve estimates, assumptions, risks and uncertainties. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. “Forward-looking statements” may be preceded by words such as “may,” “future,” “plan” or “planned,” “will,” “should,” “expected,” “anticipates,” “continue,” “eventually,” “believes,” or “projected.” Forward-looking statements include statements concerning continued or additional deployments or success of deployments and success of our products; our breakeven point and obtainment of efficiencies; ; the potential market for ContraPest; the potential impact and effects of the COVID-19 pandemic on the Company’s business, results of operations and financial performance; any measures the Company has and may take in response to COVID-19 and any expectations the Company may have with respect thereto; the Company’s strategy and target marketing and markets; continuing the Company’s vision; expected benefits of the Company’s initiatives and continuation of those initiatives; the continuation or expansion of the use of ContraPest; demand for ContraPest; the Company’s expectation regarding costs, expenses and cash and continuing its cost improvement plan; future financial results; and the Company’s execution of its strategic business plan.

Investors should not unduly rely on forward-looking statements. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those made in the forward-looking statements, including as a result of various factors and other risks, such as market acceptance and demand for the Company’s products, customers completing order commitments, the Company’s ability to reduce costs and execute on its plans and continuing to believe it is following the best strategy, the Company having sufficient financing, and other factors identified in the Company’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K and quarterly reports filed on Form 10-Q. All forward-looking statements speak only as of the date on which they were made based on management’s assumptions as of such date. The Company does not undertake any obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT: 

Investors: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC,
602-889-9700, [email protected]

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc.,
928-779-4143

 


SENESTECH, INC.


CONDENSED BALANCE SHEETS


(In thousands, except shares and per share data)

December 31,

December 31,

2020

2019


ASSETS

Current assets:

Cash

$           3,643

$           1,936

Accounts receivable trade, net

25

26

Accounts receivable-other

123

Prepaid expenses

178

257

Inventory

945

1,180

Deposits

28

20

Total current assets

4,819

3,542

Right to use asset-operating leases

665

699

Property and equipment, net

538

738

Total assets

$           6,022

$           4,979


LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Short-term debt

$                98

$              123

Accounts payable

404

265

Accrued expenses

292

1,193

Total current liabilities

794

1,581

Long-term debt, net

673

137

Operating lease liability

671

694

Total liabilities

2,138

2,412

Commitments and contingencies (See note 12)

Stockholders’ equity:

Common stock, $0.001 par value, 100,000,000 shares authorized, 5,099,512 and 1,414,671
shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively

5

1

Additional paid-in capital

108,119

98,433

Accumulated deficit

(104,240)

(95,867)

Total stockholders’ equity

3,884

2,567

Total liabilities and stockholders’ equity

$           6,022

$           4,979

 


SENESTECH, INC.


CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS


(In thousands, except shares and per share data)

For the Years

Ended December 31,

2020

2019

Grant revenue

$           24

$              –

Sales

258

143

Cost of sales

281

101

Gross profit 

1

42

Operating expenses:

Research and development

1,494

1,908

Selling, general and administrative

6,440

8,421

Total operating expenses

7,934

10,329

Net operating loss

(7,933)

(10,287)

Other income (expense):

Interest income

3

45

Interest expense

(28)

(42)

Other income (expense)

21

266

Total other income (expense)

(4)

269

Net loss and comprehensive loss

(7,937)

(10,018)

Warrant revaluation 

11

Deemed dividend-warrant price protection-revaluation adjustment

436

Net loss attributable to common shareholders

$    (8,373)

$  (10,029)

Weighted average common shares outstanding – basic and fully diluted

3,006,475

1,304,045

Net loss per common share – basic and fully diluted

$      (2.78)

$      (7.69)

 


SenesTech Inc.


Itemized Reconciliation Between Net Loss and Non-GAAP Adjusted EBITDA


For the Years Ended December 31, 2020 and 2019


(Unaudited)

(in thousands)

For the Years

Ended December 31, 

2020

2019

Net Loss (As Reported, GAAP)

$ (7,937)

$ (10,018)

Non-GAAP Adjustments:

Interest and dividends

25

(3)

Stock-based compensation

645

873

(Gain) loss on sale of assets

(21)

3

Gain on litigation reserve revaluation

(269)

Change in reserves for uncollectable receivables

123

Reserve for future severance payments

684

Reserve for inventory obsolescence

119

Amortization and accretion:

Depreciation expense

288

413

Total of non-GAAP adjustments

1,056

1,824

Adjusted EBITDA Loss (Non-GAAP)

$ (6,881)

$   (8,194)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/senestech-announces-year-end-2020-financial-and-operational-results-301256260.html

SOURCE SenesTech, Inc.

BIOLASE Reports 31% Sequential Revenue Growth In 2020 Fourth Quarter; Demand From New Users Driving Positive Performance

Guides for Significant Revenue Growth Year Over Year in First Quarter 2021

PR Newswire

FOOTHILL RANCH, Calif., March 25, 2021 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the fourth quarter and full year ended December 31, 2020.

2020 Fourth Quarter Operating Highlights and Recent Developments
:

  • Total revenue was $8.5 million, representing sequential quarterly growth of 31%.
  • U.S. revenue exceeded the prior-year fourth quarter, despite COVID-19 headwinds.
  • 78% of sales came from new users, continuing a positive trend.
  • 40% of sales came from dental specialists, a significant increase compared to recent prior periods.
  • Several Dental Services Organizations (“DSOs”) purchased BIOLASE products in the fourth quarter, including Heartland Dental, Dental Care Alliance, Aspen Dental and Virginia Family Dentistry.
  • BIOLASE significantly bolstered its balance sheet during the COVID-19 pandemic as cash and cash equivalents totaled $17.9 million on December 31, 2020.
  • The Company completed a $14.4 million bought deal in February 2021 increasing its current cash and cash equivalents to approximately $40.0 million as of February 28, 2021, including the proceeds from the exercise of warrants sold in the Company’s July 2020 rights offering.

“Our strong fourth quarter revenue performance is our second consecutive quarter of significant sequential growth and was driven by sales to new customers, dental specialists and DSOs in the U.S.,” commented John Beaver, President and Chief Executive Officer. “Dental specialists, such as endodontist and periodontists, comprised 40% of our U.S. laser sales in the fourth quarter, reflecting our ongoing efforts to educate and train these dental specialists on the benefits of our lasers to drive increased adoption. Our industry-leading dental lasers provide a new, improved and better standard of care for dental procedures while ensuring a safer environment for dental practitioners and patients by reducing aerosolization to mitigate the spread of infectious pathogens, such as COVID-19. We are experiencing high demand from dental specialists for our advanced dental lasers because these products provide the opportunity they seek for safer, more advanced alternatives to grow their practices.

“We have continued to make adjustments to our go-to-market approach during the pandemic, and the momentum we are seeing in the current 2021 first quarter gives us greater confidence that we are nearing a resumption of the growth we were generating prior to COVID-19. Specifically, despite the ongoing impact of the pandemic, we expect to report total revenue growth of approximately 65% for the current first quarter compared to the same quarter a year ago.”  

2020 Fourth Quarter Financial Results

Net revenue for the fourth quarter of 2020 was $8.5 million, an increase of 31% sequentially from third quarter revenue of $6.5 million. Compared to the year-ago fourth quarter, which was the last full quarter prior to the impact of the COVID-19 pandemic, revenue decreased 17% from $10.2 million. U.S. laser revenue was $3.8 million for the fourth quarter of 2020, up 15% when compared to U.S. laser revenue of $3.3 million for the fourth quarter of 2019. U.S. consumables and other revenue for the fourth quarter of 2020, which consists of revenue from consumable products such as disposable tips, decreased 10% compared to the fourth quarter of 2019. Outside the U.S., laser revenue declined 52% to $1.7 million for the fourth quarter of 2020 compared to $3.5 million for the fourth quarter of 2019, and consumables and other revenue decreased 13% year over year as recovery from the pandemic has come slower internationally.

Gross margin for the fourth quarter of 2020 was 19%, compared to 43% for the fourth quarter of 2019. The lower gross margin reflects the impact of a decline in revenues relative to our fixed costs and a $1.0 million expense for inventory obsolescence. These impacts were partially offset by higher average U.S. selling prices of our lasers. Total operating expenses were $7.1 million for the fourth quarter of 2020 compared to $7.5 million for the fourth quarter of 2019, a decrease of approximately 5%. Operating loss for the fourth quarter of 2020, was $5.5 million, compared to an operating loss of $3.0 million in the fourth quarter of 2019. Net loss for the fourth quarter of 2020 was $6.1 million, or $0.07 per share, compared to a net loss of $3.6 million, or $0.13 per share, for the fourth quarter of 2019.

Full Year 2020 Financial Results

Net revenue for the year ended December 31, 2020 was $22.8 million, a decrease of 40% compared to net revenue of $37.8 million for the year ended December 31, 2019. U.S. laser revenue was $8.3 million for the year ended December 31, 2020, a decrease of 25% compared to U.S. laser revenue of $11.1 million for the year ended December 31, 2019. U.S. consumables and other revenue for the year ended December 31, 2020, which consists of revenue from consumable products such as disposable tips, decreased 29% year over year. International laser revenue decreased to $4.0 million for the year ended December 31, 2020 compared to $11.7 million for the year ended December 31, 2019.

Gross margin for the year ended December 31, 2020 was 27% compared to 38% for the year ended December 31, 2019. Total operating expenses were $24.7 million for the year ended December 31, 2020 compared to $29.9 million for the year ended December 31, 2019, a decrease of $5.2 million, or 17%, year over year. Operating loss for the year ended December 31, 2020 was $18.5 million, compared to an operating loss of $15.6 million for the year ended December 31, 2019, an increase of $2.9 million year over year. Net loss for the year ended December 31, 2020 was $16.8 million, or $0.28 per share, compared to a net loss of $17.9 million, or $0.77 per share, for the year ended December 31, 2019.

Adjusted EBITDA – Use of Non-GAAP Measures

The Reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company’s non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company’s Adjusted EBITDA and Adjusted EBITDA per share.

Adjusted EBITDA loss for the fourth quarter of 2020 was $4.5 million, or $0.05 per share, compared with Adjusted EBITDA loss of $1.7 million, or $0.05 per share, for the fourth quarter of 2019.

Adjusted EBITDA for the year ended December 31, 2020 was a loss of $13.4 million, or $0.22 per share, compared with an Adjusted EBITDA loss of $10.3 million, or $0.45 per share, for the year ended December 31, 2019.

2021 First Quarter Revenue Guidance

For the first quarter ending March 31, 2021, the Company expects total revenue of $7.5 million to $8.0 million, which would represent growth between 60% and 70% year over year.

Conference Call Information

BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the fourth quarter and full year ended December 31, 2020, and to answer questions. For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 800-353-6461. For international participants outside the U.S./Canada, the dial-in number is 334-323-0501. For all callers, refer to the Conference ID 7623727. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see “Investor Events”.

An audio archive of the webcast will be available for 30 days on the Investor Relations section of the BIOLASE website.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE’s expected revenue and revenue growth during the first quarter of 2021. Forward-looking statements can be identified through the use of words such as may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s most recent annual report filed on Form 10-K and quarterly report filed on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

Tables to Follow


BIOLASE, INC.


CONSOLIDATED STATEMENTS OF OPERATIONS


(Unaudited)


(In thousands, except per share data)


Three Months Ended


Twelve Months Ended


December 31,


December 31,


2020


2019


2020


2019

Net revenue

$

8,520

$

10,182

$

22,780

$

37,799

Cost of revenue

6,915

5,765

16,607

23,511

Gross profit

1,605

4,417

6,173

14,288

Operating expenses:

Sales and marketing

3,767

3,731

11,242

14,396

General and administrative

2,326

2,634

9,772

10,748

Engineering and development

1,051

1,100

3,695

4,765

Total operating expenses

7,144

7,465

24,709

29,909

Loss from operations

(5,539)

(3,048)

(18,536)

(15,621)

(Gain) loss on foreign currency transactions

(47)

53

21

121

Interest expense, net

577

598

2,359

2,157

Other (income) expense, net

(6)

(4,215)

Non-operating (loss) gain

524

651

(1,835)

2,278

Loss before income tax provision

(6,063)

(3,699)

(16,701)

(17,899)

Income tax provision (benefit)

79

(112)

128

(44)

Net loss

$

(6,142)

$

(3,587)

$

(16,829)

$

(17,855)

Net loss

$

(6,142)

$

(3,587)

$

(16,829)

$

(17,855)

Deemed dividend on convertible preferred stock

(17,378)

Net loss attributable to common stockholders

$

(6,142)

$

(3,587)

$

(34,207)

$

(17,855)

Net loss per share attributable to common stockholders:

Basic

$

(0.07)

$

(0.13)

$

(0.56)

$

(0.77)

Diluted

$

(0.07)

$

(0.13)

$

(0.56)

$

(0.77)

Shares used in the calculation of net loss per share:

Basic

93,211

28,118

61,136

23,201

Diluted

93,211

28,118

61,136

23,201

 


BIOLASE, INC.


CONSOLIDATED BALANCE SHEETS


(In thousands, except per share data)


December 31,


December 31,


2020


2019


(Unaudited)


(Audited)


ASSETS

Current assets:

Cash and cash equivalents

$

17,564

$

5,789

Restricted cash

312

312

Accounts receivable, less allowance of $4,017 and $2,531 in 2020 and
2019, respectively

3,059

8,760

Inventory

11,157

10,995

Prepaid expenses and other current assets

3,018

1,163

Total current assets

35,110

27,019

Property, plant and equipment, net

782

1,193

Goodwill

2,926

2,926

Right of use asset

1,976

276

Other assets

231

433


Total assets

$

41,025

$

31,847


LIABILITIES, REDEEMABLE PREFERRED STOCK AND


STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

2,651

$

5,332

Accrued liabilities

6,667

4,744

Deferred revenue, current portion

1,905

2,237


Total current liabilities

11,223

12,313

Deferred revenue

374

358

Warranty accrual

384

245

Non current term loans, net of discount

16,186

13,466

Non current operating lease liability

1,774

4

Other liabilities

1,056

1,119


Total liabilities

30,997

27,505

Redeemable preferred stock:

Series E Preferred stock, par value $0.001 per share

3,965


Total redeemable preferred stock

3,965

Stockholders’ equity:

Series F Preferred stock, par value $0.001 per share

118

Common stock, par value $0.001 per share

98

31

Additional paid-in capital

261,573

235,594

Accumulated other comprehensive loss

(385)

(701)

Accumulated deficit

(251,376)

(234,547)


Total stockholders’ equity

10,028

377


Total liabilities, redeemable preferred stock and stockholders’ equity

$

41,025

$

31,847

 


BIOLASE, INC.


CONSOLIDATED STATEMENTS OF CASH FLOWS


(Unaudited, in thousands)


Twelve Months Ended


December 31,


2020


2019


Cash Flows from Operating Activities:

Net loss

$

(16,829)

$

(17,855)

Adjustments to reconcile net loss to net cash and cash equivalents used in
operating activities:

  Depreciation and amortization

499

982

  Provision for bad debts

1,328

1,695

  Provision for sales returns

87

  Provision for inventory excess and obsolescence

(591)

413

  Inventory disposals

1,300

15

  Amortization of discounts on lines of credit

165

140

  Amortization of debt issuance costs

331

188

  Change in fair value of warrants

(5,850)

  Issuance costs for common stock warrants

1,641

  Stock-based compensation

3,370

2,742

  Warrants issued to consultants

48

  Deferred income taxes

7

  Earned interest income

2

  Changes in operating assets and liabilities:

  Accounts receivable

4,286

655

  Inventory

(871)

825

  Prepaid expenses and other current assets

825

439

  Accounts payable and accrued liabilities

(2,107)

(3,156)

  Deferred revenue

(379)

114

Net cash and cash equivalents used in operating activities

(12,795)

(12,746)


Cash Flows from Investing Activities:

 Purchases of property, plant, and equipment

(96)

(207)

Net cash and cash equivalents used in investing activities

(96)

(207)


Cash Flows from Financing Activities:

  Proceeds from the issuance of common stock

6,912

9,171

  Proceeds from the issuance of Series F Convertible Preferred Stock

2,700

  Proceeds from the issuance of July 2020 Warrants

15,300

  Payments of equity offering costs

(1,281)

(821)

  Payments of warrant issuance costs

(1,640)

  Borrowings on other long-term loans

3,140

  Borrowings under term loan

2,500

  Principal payment on term loan

(700)

  Borrowings on credit facility

3,000

  Repayment of credit facility

(3,000)

  Payment of debt issuance costs

(128)

(133)

  Proceeds from the exercise of common stock warrants

46

  Proceeds from exercise of stock options

4

Net cash and cash equivalents provided by financing activities

24,349

10,721

  Effect of exchange rate changes

317

(23)

  Decrease in cash, cash equivalents and restricted cash

11,775

(2,255)

Cash, cash equivalents and restricted cash, beginning of period

6,101

8,356

Cash, cash equivalents and restricted cash, end of period

$

17,876

$

6,101

Supplemental cash flow disclosure:

  Cash paid for interest

$

1,881

$

1,784

  Cash received for interest

$

11

$

  Cash paid for income taxes

$

22

$

35

  Cash paid for operating leases

$

489

$

797

  Non-cash accrual for capital expenditures

$

$

18

  Non-cash settlement of performance award liability

$

151

$

201

  Non-cash right-of-use assets obtained in exchange for lease obligation

$

2,037

$

276

  Equity financing costs in accounts payable

$

74

$

129

  Deemed dividend on convertible preferred stock

$

17,378

$

  Forgiveness of debt

$

10

$

  Warrants exercised in other receivables

$

1,498

$

  Warrants issued in connection with debt instruments

$

67

$

161

Non-GAAP Disclosure

In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. (“GAAP”), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents. In 2019, the Company revised its non-GAAP financial measures to include the change in allowance for doubtful accounts in an effort to better align its Adjusted EBITDA with its loan covenants and how management evaluates business performance.

Adjusted EBITDA is defined as net income (loss) before interest, taxes, depreciation and amortization, stock-based compensation, and allowance for doubtful accounts. Management uses Adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.


BIOLASE, INC.


Reconciliation of GAAP Net Loss to Adjusted EBITDA


(Unaudited)


(In thousands, except per share data)


Three Months Ended


Twelve Months Ended


December 31,


December 31,


2020


2019


2020


2019

GAAP net loss attributable to common stockholders

$

(6,142)

$

(3,587)

$

(34,207)

$

(17,855)

Deemed dividend on convertible preferred stock

17,378

GAAP net income (loss)

$

(6,142)

$

(3,587)

$

(16,829)

$

(17,855)

Adjustments:

Interest expense, net

577

598

2,359

2,157

Income tax (benefit) provision

79

(112)

128

(44)

Depreciation and amortization

(28)

228

499

982

Change in allowance for doubtful accounts

65

452

1,328

1,695

Stock-based compensation

1,003

768

3,370

2,742

Other (income) expense, net

(6)

(4,215)

Adjusted EBITDA

$

(4,452)

$

(1,653)

$

(13,360)

$

(10,323)

GAAP net loss attributable to common stockholders
per share, basic and diluted

$

(0.07)

$

(0.13)

$

(0.56)

$

(0.77)

Deemed dividend on convertible preferred stock

0.28

GAAP net income (loss) per share, basic and diluted

$

(0.07)

$

(0.13)

$

(0.28)

$

(0.77)

Adjustments:

Interest expense, net

0.01

0.02

0.04

0.09

Income tax (benefit) provision

Depreciation and amortization

0.01

0.01

0.04

Change in allowance for doubtful accounts

0.02

0.02

0.07

Stock-based compensation

0.01

0.03

0.06

0.12

Other (income) expense, net

(0.07)

Adjusted EBITDA per share, basic and diluted

$

(0.05)

$

(0.05)

$

(0.22)

$

(0.45)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biolase-reports-31-sequential-revenue-growth-in-2020-fourth-quarter-demand-from-new-users-driving-positive-performance-301256277.html

SOURCE BIOLASE, Inc.

Avidity Biosciences to Participate in Upcoming Investor Conferences

PR Newswire

LA JOLLA, Calif., March 25, 2021 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs), today announced that management will be participating in the following virtual investor conferences:

  • Guggenheim Healthcare Talks—Genomic Medicines and Rare Disease Day Conference

    Thursday, April 1
    st, 2021, 6:00 am PDT
    • Panel on Duchenne Muscular Dystrophy (DMD)
    • Participants include:
      • Arthur Levin, PhD, Chief Scientific Officer, Avidity Biosciences
      • Michael Binks, MD, Vice President of Clinical Research, Pfizer
      • Louise Rodino-Klapac, PhD, Chief Scientific Officer, Sarepta Therapeutics
      • Carl Morris, PhD, Chief Scientific Officer, Solid Biosciences
      • Sam Wadsworth, Chief Scientific Officer, Ultragenyx Pharmaceutical
  • 2021 Virtual Wells Fargo Biotech Corporate Access Day

    Tuesday, April 6
    th, 2021
    • Avidity management participation in investor 1×1 meetings
  • 20th Annual Needham Virtual Healthcare Conference

    Monday, April 12
    th, 2021, 12:45pm PDT
    • Webcast presentation

Live webcasts of the Guggenheim panel and Needham presentation will be available on the Investors section of Avidity’s website and a replay of both events archived on the site.

About Avidity
Avidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that are designed to overcome current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity’s proprietary AOC platform combines the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity’s lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its other muscle programs are focused on the treatment of Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, Pompe disease and muscle atrophy. In addition to its muscle franchise, Avidity has research efforts focused on immune, cardiac and other cell types.  

Avidity is headquartered in La Jolla, CA. For more information about Avidity’s science, pipeline and people, please visit www.aviditybiosciences.com and engage with Avidity on LinkedIn

Contacts:

Company:

Mike MacLean

(858) 401-7900
[email protected]          

Media and Investors:

Amy Conrad

Juniper Point
(858) 366-3243
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-301256325.html

SOURCE Avidity Biosciences, Inc.